Tectonic Therapeutic Q3 net loss $17.7M; TX45 Phase 1b enrollment ahead; new HHT candidate TX2100

Tectonic Therapeutic, Inc.

2024-Q3 EPS reported -$7.16

Net loss of $17.7M for Q3 2024 vs $10.1M a year ago; R&D spend $14.3M (up from $8.1M) on TX45 trials.
Cash $159.1M as of Sept 30, 2024; runway into mid-2027 covering key readouts and HHT program.
Phase 1b hemodynamic trial for TX45 enrollment ahead of plan; topline results expected late Q1 2025/early Q2 2025.
First subject dosed in TX45 APEX Phase 2 trial in Oct 2024; topline data expected 2026.
TX2100 development candidate selected for HHT (no approved therapy); Phase 1 trial expected Q4 2025/Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.